Tectonic Therapeutic Reports Positive Phase 1 Data for Rare Vascular Drug TX2100
TX2100 cleared Phase 1a safety hurdles and earned FDA Fast Track Designation for hereditary hemorrhagic telangiectasia, a rare disorder with no approved treatments.
Tectonic Therapeutic on Monday disclosed favorable safety, tolerability, and pharmacokinetic results from its Phase 1a trial of TX2100, an investigational antibody targeting the APJ receptor, tested in healthy adult volunteers. The Watertown, Massachusetts-based biotechnology company said the data support advancing the drug candidate into a Phase 1b study in patients with Hereditary Hemorrhagic Telangiectasia, known as HHT.
HHT is a rare, inherited vascular disorder characterized by abnormal blood vessel formation. No therapies have received regulatory approval for the condition, making the patient population an area of significant unmet medical need.
Read more Pathology Ventures Appoints Dominic Stockey as Executive VP →
The U.S. Food and Drug Administration granted TX2100 Fast Track Designation for HHT, a status that can accelerate the review process for drugs addressing serious conditions. Separately, the FDA cleared Tectonic's Investigational New Drug application to conduct the upcoming Phase 1b trial in American patients with the disease.
TX2100 is designed as a VHH-Fc fusion antagonist antibody, a molecular format that Tectonic employs to modulate G-protein coupled receptors — a class of biological targets the company has built its platform around. The Phase 1a trial was structured to generate data needed to support the next stage of clinical development.
Tectonic Therapeutic trades on the Nasdaq under the ticker TECX. Continue reading at GlobeNewswire - Industry News on Financial Services.
